# US 2012/0251497 A1 · Inhibitors of hepatitis c virus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251497 A1
- Document ID: US20120251497A1
- Status: Published application
- Kind: A1
- Application number: 13/456,181
- Filed: 2012-04-25
- Published: 2012-10-04
- Earliest claimed: 2010-10-26
- Assignees: Presidio Pharmaceuticals, Inc.
- Inventors: Min Zhong; Leping Li
- Web page: https://patentgrep.com/patent/US20120251497A1

## CPC

- C07D 491/048: the oxygen-containing ring being five-membered
- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 31/4355: the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/5513: 1,4-Benzodiazepines, e.g. diazepam {or clozapine}
- A61K 31/553: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A61K 31/7056: containing five-membered rings with nitrogen as a ring hetero atom
- A61K 38/212: {IFN-alpha}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 307/84: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 471/14: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 491/14: Ortho-condensed systems
- C07D 498/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A class of compounds that inhibit Hepatitis C Virus (HCV) is disclosed, along with compositions containing the compound, and methods of using the composition for treating individuals infected with HCV.

## Claims

### Claim 1

A compound according to structural Formula XIV:
wherein:
R′1 is selected from
H, —F, —Cl, —Br, and —I;
R′2 is selected from —OH, —OCH3,
X′ is selected from ═O, ═N—OH, ═N—O(CH2CH2O)0-8CH3, and ═N—O(CH2)1-23CH3, and
R′3 is selected from —CH3 and —OCH3.

### Claim 2 (depends on 1)

The compound of claim 1, wherein
R′1 is
R′2 is selected from —OH, —OCH3,
X′ is ═O, and
R′3 is —CH3.

### Claim 3 (depends on 1)

The compound of claim 1, wherein
R′1 is
R′2 is selected from —OH, —OCH3,
X′ is ═O, and
R′3 is —OCH3.

### Claim 4 (depends on 1)

The compound of claim 1, wherein
R′1 is
R′2 is selected from —OH, —OCH3,
X′ is selected from ═N—OH, ═N—OCH3, ═N—OCH2CH2OCH3, ═N—O(CH2CH2O)2CH3, and ═N—O(CH2CH2O)3CH3, and
R′3 is —CH3.

### Claim 5 (depends on 1)

The compound of claim 1, wherein
R′1 is —F,
R′2 is selected from —OH, —OCH3,
X′ is selected from ═N—OH, ═N—OCH3, ═N—OCH2CH2OCH3═N—O(CH2CH2O)2CH3 and ═N—O(CH2CH2O)3CH3, and
R′3 is —CH3.

### Claim 6 (depends on 1)

The compound of claim 1, wherein
R′1 is —F,
R′2 is selected from —OH, —OCH3,
X′ is ═O, and
R′3 is —CH3.

### Claim 7 (depends on 1)

The compound of claim 1, wherein
R′1 is —F,
R′2 is selected from —OH, —OCH3,
X′ is ═O, and
R′3 is —OCH3.

### Claim 8 (depends on 1, 5, 6, 7)

The compound of any one of claims 1 and 5-7, wherein R′1 is para-F.

### Claim 9 (depends on 1, 2, 3, 4)

The compound of any one of claims 1-4, wherein R′1 is para-

### Claim 10

A compound according to structural Formula XIV-a:
wherein:
R′1 is selected from
—H, —F, —Cl, —Br, and —I;
R′2 is selected from —OH, —OCH3,
R′3 is selected from —CH3 and —OCH3.

### Claim 11 (depends on 10)

The compound of claim 10, wherein
R′1 is
R′2 is selected from —OH, —OCH3,
R′3 is —CH3.

### Claim 12 (depends on 10)

The compound of claim 10, wherein
R′1 is
R′2 is selected from —OH, —OCH3,
and
R′3 is —OCH3.

### Claim 13 (depends on 10)

The compound of claim 10, wherein
R′1 is —F,
R′2 is selected from —OH, —OCH3,
and
R′3 is —CH3.

### Claim 14 (depends on 10)

The compound of claim 10, wherein
R′1 is —F,
R′2 is selected from —OH, —OCH3,
and
R′3 is —OCH3.

### Claim 15 (depends on 10, 13, 14)

The compound of any one of claims 10, 13 and 14, wherein R′1 is para-F.

### Claim 16 (depends on 10, 11, 12)

The compound of any one of claims 10 to 12, wherein R′1 is para-

### Claim 17

A compound according to structural Formula XIV-a:
wherein:
R′1 is selected from para-
and para-F,
R′2 is selected from
and
R′3 is selected from —CH3 and —OCH3.

### Claim 18

A compound having the structure:
where R′1 is either para-
or para-F,
is a residue of an amino acid according to the structure:
where Raa is the side-chain of the amino acid, and
R′3 is selected from —CH3 and —OCH3.

### Claim 19 (depends on 18)

The compound of claim 18, wherein
is a residue of an amino acid selected from the group consisting of D/L-, D- or L-alanine, isoleucine, leucine, valine, phenylalanine, tryptophan, tyrosine, asparagine, cysteine, glutamine, methionine, serine, threonine, aspartic acid, glutamic acid, arginine, histidine, lysine, glyine, and proline.

### Claim 20

A compound selected from the group consisting of B243, B244, B245, B246, B247, B248, B249, B250, B251, B252, B253, B254, B255, B256, B257, B258, B259, B260, B261, B262, B263, B264, B265, B266, B267, B268, B269, B270, B271, B272, B273, B274, B275, B276, B277, B278, B279, B280, B281, B282, B283, B284, B285, B286, B287, B288, B289, D8, D9, D10, D11, D12, D13, D14, D26, D27, D37, D38, D42, D43, D44, D45, D46, D47, D48, D49, D50, D51, D52, D53, D54, D55, D56, D57, D71, D72, D75, D76, D77, D78, D79. D80, D81, D82, D83, D84, D85, D86, D87, D88, D89, and D90.

### Claim 21 (depends on 20)

A compound of claim 20 selected from B243, B244, B245, B246, B248, B249, B252, B253, B254, B255, B256, B257, B258, B259, B260, B261, B263, B264, B265, B266, B267, B268, B269, B270, B271, B272, B273, B275, B276, B277, B278, B280, B281, B282, B283, B284, B285, B286, and B289.

### Claim 22

A compound having the structure:

### Claim 23 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 together with one or more pharmaceutically acceptable excipients or vehicles, and optionally other therapeutic and/or prophylactic ingredients.

### Claim 24 (depends on 23)

A pharmaceutical compound of claim 23, wherein the compound is

### Claim 25 (depends on 23)

The composition of claim 23, with further comprises additional one, two or three anti-HCV agent(s) selected from the group consisting of interferon-alpha, ribavirin, cyclosporine derivatives, NS3 protease inhibitors, NS4B inhibitors, NS5A inhibitors, NS5B polymerase inhibitors, and p7 inhibitors.

### Claim 26 (depends on 1)

A method of treating HCV infection in a subject comprising administering to the subject, a pharmaceutically acceptable dose of the compound of claim 1, and continuing the administering until a selected reduction in the subject's HCV titer is achieved.

### Claim 27 (depends on 26)

The method of claim 26, wherein the compound is selected from B243, B244, B245, B246, B248, B249, B252, B253, B254, B255, B256, B257, B258, B259, B260, B261, B263, B264, B265, B266, B267, B268, B269, B270, B271, B272, B273, B275, B276, B277, B278, B280, B281, B282, B283, B284, B285, B286, and B289.

### Claim 28 (depends on 26)

The method of claim 26, wherein the administering is by oral administration.

### Claim 29 (depends on 1)

A compound of claim 1 for use in treating HCV infection in an infected subject.
